Corvus Pharmaceuticals, Inc. (CRVS) Stock Price & Analysis
Corvus Pharmaceuticals, Inc. (CRVS) rose 0.18% to USD 11.17 as of June 10, 2026 at 02:39 UTC, according to Nexqual real-time market data.
CRVS last closed at USD 11.15; the session ranged USD 10.83–11.49 on volume of 1,578,722 shares. Market capitalization is $939.29M, with a 52-week range of USD 3.55–26.95 (NGM). Source: Nexqual, June 10, 2026 at 02:39 UTC.
Key Statistics (as of June 10, 2026 at 02:39 UTC)
| Price | USD 11.17 |
|---|---|
| Change | ▲ 0.18% (up) |
| Previous Close | USD 11.15 |
| Open | USD 11.24 |
| Day Range | USD 10.83 – 11.49 |
| 52-Week Range | USD 3.55 – 26.95 |
| Volume | 1,578,722 shares |
| Market Cap | $939.29M |
| Exchange | NGM |
Technical Analysis (CRVS)
Nexqual's technical model rates CRVS "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.89 (oversold) |
| vs SMA50 | Below (USD 14.24) |
| MACD | -0.94 (negative) |
Analyst Ratings (CRVS)
Wall Street analysts rate CRVS "Strong Buy" based on 6 analysts, with a mean price target of USD 33.33 (range USD 27–42), per Nexqual as of June 10, 2026 at 02:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 33.33 |
| High Target | USD 42 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (CRVS)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.17 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.15 ▲ beat |
| 2025-12-31 | USD -0.15 vs est -0.13 ▼ miss |
| 2025-09-30 | USD -0.12 vs est -0.14 ▲ beat |
| 2025-06-30 | USD -0.13 vs est -0.12 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Financials & Fundamentals (CRVS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -30.46% |
| Debt / Equity | 0.35 |
| Current Ratio | 19.81 |
| Total Cash | $236.71M |
| Total Debt | $834,000 |
| Free Cash Flow | $-22.57M |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Financial Health Score (CRVS)
Nexqual rates Corvus Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:39 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $237M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$35M |
| Efficiency | Critical — ROE -30%, ROA -19.2% |
Ownership (CRVS)
| Insider Ownership | +3.51% |
|---|---|
| Institutional Ownership | +85.12% |
| Shares Outstanding | 84.09M |
| Float | 72.78M |
| Short % of Float | +23.42% |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Leadership (CRVS)
Corvus Pharmaceuticals, Inc. is led by Richard A. Miller (age 74), Co-Founder, President, CEO & Chairman of the Board, per Nexqual as of June 10, 2026 at 02:39 UTC.
| Co-Founder, President, CEO & Chairman of the Board | Richard A. Miller (age 74) |
|---|---|
| Co-Founder & Independent Director | Peter A. Thompson FACP (age 65) |
| Chief Financial Officer | Leiv Lea (age 71) |
| Senior Vice President of Pharmaceutical Development | William Benton Jones (age 59) |
Major Backers & Investors (CRVS)
Notable institutional backers of Corvus Pharmaceuticals, Inc. include Orbimed Advisors LLC., Adams Street Partners, LLC, Price (T.Rowe) Associates Inc, according to Nexqual as of June 10, 2026 at 02:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 8.52% |
| Adams Street Partners, LLC | 3.9% |
| Price (T.Rowe) Associates Inc | 3.47% |
| Vivo Capital, LLC | 3.34% |
| Morgan Stanley | 2.97% |
| Deep Track Capital, Lp | 2.96% |
| Wellington Management | 2.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.14% |
| Vanguard Group | 7.61% |
| State Street | 7.02% |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
From Corvus Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
- The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
- It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer.
- It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CYPH | Cypherpunk Technologies Inc. | USD 0.68 | ▲ 30.17% |
| CTMX | CytomX Therapeutics, Inc. | USD 2.98 | ▼ 0.67% |
| EDSA | Edesa Biotech, Inc. | USD 4.94 | ▼ 9.52% |
| PTGX | Protagonist Therapeutics, Inc. | USD 105.87 | ▲ 8.72% |
| ACIU | AC Immune SA | USD 2.26 | ▲ 0.44% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:39 UTC. This page is informational and not investment advice.